Phase 2 study of TriRima for treatment resistant depression
CeNeRx BioPharma reported that it has initiated a Phase 2 trial of TriRima as monotherapy for treatment resistant depression. The trial is a double blind, placebo-controlled study designed to assess the efficacy of TriRima administered twice daily as monotherapy in patients with treatment resistant depression. Secondary objectives include evaluating TriRima's safety and tolerability and assessing its pharmacokinetic profile.
TriRima is a member of a class of drugs known as RIMAs, or reversible and selective inhibitors of monoamine oxidase A (MAO-A). MAO inhibitors achieve superior "triple-action" antidepressant efficacy by elevating the levels of all three of the key neurotransmitters that positively affect mood. However, older MAO inhibitors have been limited by their potential to cause serious cardiovascular side effects when foods containing the naturally occurring substance tyramine are consumed. TriRima is designed to achieve the efficacy of the MAO inhibitor class while reducing or eliminating the risk of these food-associated effects.
For more information call (919) 234-4072 or visit www.cenerx.com.